Skip to main content

Drug Interactions between pralatrexate and probenecid

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

probenecid PRALAtrexate

Applies to: probenecid and pralatrexate

MONITOR: Coadministration with probenecid may result in delayed clearance and increased plasma concentrations of pralatrexate. The mechanism involves inhibition of the active tubular secretion of pralatrexate, which is approximately 34% eliminated unchanged by the kidney.

MANAGEMENT: Caution is advised if pralatrexate is prescribed in combination with probenecid. Complete blood cell counts as well as renal and hepatic function should be closely monitored. Treatment interruption or dose reduction of pralatrexate may be required if toxicities such as mucositis, myelosuppression, or liver enzyme abnormalities develop. Patients should be advised to contact their physician if they develop oral ulcers, painful swallowing, vomiting, diarrhea, and/or signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.

References

  1. (2009) "Product Information. Folotyn (pralatrexate)." Allos Therapeutics

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer